Skip to Content

Doptelet Approval History

Reviewed by J.Stewart B.Pharm Last updated on May 23, 2018.

FDA Approved: Yes (First approved May 21, 2018)
Brand name: Doptelet
Generic name: avatrombopag
Dosage form: Tablets
Company: Dova Pharmaceuticals, Inc.
Treatment for: Thrombocytopenia

Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical procedure.

Dosage and Administration

  • Doptelet tablets should be taken orally with food once daily for five consecutive days.
  • Dosing should begin 10 to 13 days prior to the scheduled medical or dental procedure, and the procedure should take place within 5 to 8 days after the last dose.
  • The recommended dose is based on a patient’s platelet count prior to the scheduled procedure.

Warnings and Precautions

Thrombotic/Thromboembolic Complications: Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Patients should be monitored carefully.

Adverse Reactions

Most common adverse reactions (≥ 3%) include: pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema.

Use In Specific Populations

  • Pregnancy: Pregnant women should be advised of the potential risk to a fetus.
  • Breastfeeding: Patients should not breastfeed during treatment with Doptelet, and for at least two weeks after taking the final dose.

Development History and FDA Approval Process for Doptelet

May 21, 2018Approval FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
Nov 27, 2017Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review
Sep 22, 2017Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.